Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CORBF
Global Cord Blood
$1.15
+9.5%
$0.95
$0.25
$2.00
$139.78M-0.64200,234 shs6,375 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$5.02
-5.7%
$5.86
$3.99
$12.88
$222.03M1.5805,416 shs627,267 shs
Pono Capital Two, Inc. stock logo
PTWO
Pono Capital Two
$11.00
+1.0%
$11.45
$8.04
$36.52
$57.42M-0.0127,253 shs12,700 shs
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$3.11
-0.6%
$4.41
$3.05
$12.36
$116.76M0.89134,781 shs46,084 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CORBF
Global Cord Blood
0.00%+31.25%-8.70%+3.96%-22.22%
LifeMD, Inc. stock logo
LFMD
LifeMD
-5.17%-5.00%+9.47%-7.48%-47.48%
Pono Capital Two, Inc. stock logo
PTWO
Pono Capital Two
0.00%0.00%0.00%0.00%-14.06%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-9.28%-19.74%-24.76%-60.97%-66.88%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CORBF
Global Cord Blood
N/AN/AN/AN/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
1.7286 of 5 stars
3.51.00.00.01.91.70.6
Pono Capital Two, Inc. stock logo
PTWO
Pono Capital Two
N/AN/AN/AN/AN/AN/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.3992 of 5 stars
0.03.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CORBF
Global Cord Blood
0.00
N/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
3.00
Buy$11.43127.89% Upside
Pono Capital Two, Inc. stock logo
PTWO
Pono Capital Two
0.00
N/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest PTWO, SERA, LFMD, and CORBF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/12/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $14.00
3/11/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/11/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$15.00 ➝ $15.00
1/8/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$10.00 ➝ $7.00
(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CORBF
Global Cord Blood
$196.12M0.71$0.82 per share1.40N/A
LifeMD, Inc. stock logo
LFMD
LifeMD
$212.45M1.05N/AN/A$0.15 per share33.43
Pono Capital Two, Inc. stock logo
PTWO
Pono Capital Two
N/AN/A$0.10 per share114.25($1.68) per shareN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$77K1,521.23N/AN/A$2.21 per share1.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CORBF
Global Cord Blood
$79.04MN/A0.00N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
-$20.60M-$0.54N/A41.79N/A-12.06%N/A-36.34%5/6/2025 (Estimated)
Pono Capital Two, Inc. stock logo
PTWO
Pono Capital Two
$340KN/A0.00N/AN/A-68.16%-5.23%N/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$36.24M-$0.99N/AN/AN/AN/A-51.73%-36.94%5/14/2025 (Estimated)

Latest PTWO, SERA, LFMD, and CORBF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/19/2025Q4 2024
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$0.23-$0.25-$0.02-$0.25$0.01 million$0.02 million
3/10/2025Q4 2024
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.04-$0.02+$0.02-$0.02$57.43 million$64.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CORBF
Global Cord Blood
N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
Pono Capital Two, Inc. stock logo
PTWO
Pono Capital Two
N/AN/AN/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CORBF
Global Cord Blood
N/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/A
0.83
0.78
Pono Capital Two, Inc. stock logo
PTWO
Pono Capital Two
N/A
0.32
0.32
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/A
2.11
2.11

Institutional Ownership

CompanyInstitutional Ownership
CORBF
Global Cord Blood
N/A
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%
Pono Capital Two, Inc. stock logo
PTWO
Pono Capital Two
60.82%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
54.64%

Insider Ownership

CompanyInsider Ownership
CORBF
Global Cord Blood
0.50%
LifeMD, Inc. stock logo
LFMD
LifeMD
15.97%
Pono Capital Two, Inc. stock logo
PTWO
Pono Capital Two
63.90%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
15.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
CORBF
Global Cord Blood
1,200121.55 millionN/ANot Optionable
LifeMD, Inc. stock logo
LFMD
LifeMD
23044.58 million36.40 millionOptionable
Pono Capital Two, Inc. stock logo
PTWO
Pono Capital Two
N/A5.22 million1.88 millionNot Optionable
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
12037.66 million28.44 millionOptionable

Recent News About These Companies

TD Cowen Sticks to Its Buy Rating for Sera Prognostics (SERA)
Sera Prognostics reports Q4 EPS (25c) vs. (25c) last year
Sera Prognostics CFO sells $27,090 in stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Global Cord Blood NYSE:CORBF

$1.15 +0.10 (+9.52%)
As of 10:15 AM Eastern

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

LifeMD stock logo

LifeMD NASDAQ:LFMD

$5.01 -0.31 (-5.73%)
As of 01:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

Pono Capital Two stock logo

Pono Capital Two NASDAQ:PTWO

Pono Capital Two, Inc. does not have any significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Pono Capital Two, Inc. was incorporated in 2022 and is based in Honolulu, Hawaii.

Sera Prognostics stock logo

Sera Prognostics NASDAQ:SERA

$3.11 -0.02 (-0.64%)
As of 01:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.